{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:09:24Z","timestamp":1792091364155,"version":"4.4.0"},"reference-count":110,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology of arterial hypertension as well as in more complex mechanisms of cardiovascular and renal diseases. RAAS-blocking agents like angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers, have long been key components in the treatment of essential hypertension, heart failure, diabetic nephropathy, and chronic kidney disease, showing benefits well beyond blood pressure reduction. Renin blockade as the first step of the RAAS cascade finally became possible in 2007 with the approval of aliskiren, the first orally active direct renin inhibitor available for clinical use and the newest antihypertensive agent on the market. In the last decade, many clinical trials and meta-analyses have been conducted concerning the efficacy and safety of aliskiren in comparison to other antihypertensive agents, as well as the efficacy and potential clinical use of various combinations. Large trials with cardiovascular and renal endpoints attempted to show potential benefits of aliskiren beyond blood pressure lowering, as well as morbidity and mortality outcomes in specific populations such as diabetics, heart failure patients, and post-myocardial infarction individuals. The purpose of this review is to present the currently available data regarding established and future potential clinical uses of aliskiren.<\/jats:p>","DOI":"10.3390\/jcm6060061","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T10:29:59Z","timestamp":1497004199000},"page":"61","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Renin Inhibition with Aliskiren: A Decade of Clinical Experience"],"prefix":"10.3390","volume":"6","author":[{"given":"Nikolaos-Dimitrios","family":"Pantzaris","sequence":"first","affiliation":[{"name":"Medical School, University of Patras, Rio Achaia 26504, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Karanikolas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Schools of Health Sciences, University of Athens75 Mikras Asias str., Athens 11527, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsiotsios","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, University Hospital of Patras, Rio Achaia 26504, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Velissaris","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, University Hospital of Patras, Rio Achaia 26504, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"key":"ref_1","unstructured":"WHO Global Health Observatory (GHO) Data (2017, February 26). Raised Blood Pressure; Situation and Trends. Available online: http:\/\/www.who.int\/gho\/ncd\/risk_factors\/blood_pressure_prevalence_text\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"ref_3","unstructured":"World Health Organization (2016). World Health Statistics\u2014Monitoring Health For The Sdgs, World Health Organization."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"SPRINT Research Group, Wright, J.T., Williamson, J.D., Whelton, P.K., Snyder, J.K., Sink, K.M., Rocco, M.V., Reboussin, D.M., Rahman, M., and Oparil, S. (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med., 373, 2103\u20132116.","DOI":"10.1056\/NEJMoa1511939"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"109","author":"Nguyen","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/ajh\/hpv045","article-title":"The Role of the (Pro)renin Receptor in Hypertensive Disease","volume":"28","author":"Danser","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/eurheartj\/ehr066","article-title":"Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study","volume":"32","author":"Verma","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cardfail.2010.06.417","article-title":"The Val-Heft Investigators. Investigators Elevated Plasma Renin Activity Predicts Adverse Outcome in Chronic Heart Failure, Independently of Pharmacologic Therapy: Data From the Valsartan Heart Failure Trial (Val-HeFT)","volume":"16","author":"Masson","year":"2010","journal-title":"J. Card. Fail."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.krcp.2016.07.004","article-title":"Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure","volume":"35","author":"Bhandari","year":"2016","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1074-5521(00)00134-4","article-title":"Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin","volume":"7","author":"Rahuel","year":"2000","journal-title":"Chem. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1124\/dmd.106.013797","article-title":"Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers","volume":"35","author":"Waldmeier","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1185\/03007990802259354","article-title":"A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects","volume":"24","author":"Vaidyanathan","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0091270006294404","article-title":"Pharmacokinetics, Safety, and Tolerability of the Oral Renin Inhibitor Aliskiren in Patients With Hepatic Impairment","volume":"47","author":"Vaidyanathan","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200746080-00003","article-title":"Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment","volume":"46","author":"Vaidyanathan","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5414\/CPP46252","article-title":"A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects","volume":"46","author":"Limoges","year":"2008","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Sustained 24-hour Blood Pressure Control in Patients with Hypertension","volume":"49","author":"Oh","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/HYPERTENSIONAHA.109.135772","article-title":"Aliskiren Monotherapy Does Not Cause Paradoxical Blood Pressure Rises: Meta-Analysis of Data From 8 Clinical Trials","volume":"55","author":"Stanton","year":"2010","journal-title":"Hypertension"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1161\/HYPERTENSIONAHA.108.109967","article-title":"The Renin Rise with Aliskiren: It\u2019s Simply Stoichiometry","volume":"51","author":"Danser","year":"2008","journal-title":"Hypertension"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood Pressure Lowering in Essential Hypertension with an Oral Renin Inhibitor, Aliskiren","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1291\/hypres.29.997","article-title":"Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension","volume":"29","author":"Kushiro","year":"2006","journal-title":"Hypertens. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","article-title":"Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan","volume":"20","author":"Pool","year":"2007","journal-title":"Am. J. Hypertens."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","article-title":"Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker","volume":"49","author":"Barton","year":"2007","journal-title":"Hypertension"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.106.084301","article-title":"Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension","volume":"49","author":"Jordan","year":"2007","journal-title":"Hypertension"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/sj.jhh.1002220","article-title":"A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension","volume":"21","author":"Strasser","year":"2007","journal-title":"J. Hum. Hypertens."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/08037050701717014","article-title":"Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension","volume":"16","author":"Verdecchia","year":"2007","journal-title":"Blood Press."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1524-6175.2007.06614.x","article-title":"Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy","volume":"9","author":"Drummond","year":"2007","journal-title":"J. Clin. Hypertens."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension","volume":"8","author":"Uresin","year":"2007","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","article-title":"Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide","volume":"25","author":"Villamil","year":"2007","journal-title":"J. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/HJH.0b013e3282f3ad9a","article-title":"Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial","volume":"26","author":"Andersen","year":"2008","journal-title":"J. Hypertens."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1470320308096411","article-title":"Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1","volume":"9","author":"Dietz","year":"2008","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/08038020802507290","article-title":"Efficacy of aliskiren\/hydrochlorothiazide single-pill combinations in aliskiren non-responders","volume":"2","author":"Nickenig","year":"2008","journal-title":"Blood Press. Suppl."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1751-7176.2009.00114.x","article-title":"Combination Therapy With Various Combinations of Aliskiren, Valsartan, and Hydrochlorothiazide in Hypertensive Patients Not Adequately Responsive to Hydrochlorothiazide Alone","volume":"11","author":"Geiger","year":"2009","journal-title":"J. Clin. Hypertens."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/hr.2008.21","article-title":"Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension","volume":"32","author":"Kushiro","year":"2009","journal-title":"Hypertens. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1016\/j.clinthera.2009.12.006","article-title":"Evaluation of the dose\u2014Response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension","volume":"31","author":"Puig","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1185\/03007990902804158","article-title":"Antihypertensive efficacy and tolerability of aliskiren\/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone","volume":"25","author":"Blumenstein","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1185\/03007990902785845","article-title":"Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension","volume":"25","author":"Littlejohn","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":"Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren: A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/jhh.2009.107","article-title":"Aliskiren for Geriatric Lowering of Systolic Hypertension: A randomized controlled trial","volume":"24","author":"Duprez","year":"2010","journal-title":"J. Hum. Hypertens."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1751-7176.2010.00378.x","article-title":"Aliskiren Alone or in Combination With Hydrochlorothiazide in Patients With the Lower Ranges of Stage 2 Hypertension: The ACQUIRE Randomized Double-Blind Study","volume":"12","author":"Black","year":"2010","journal-title":"J. Clin. Hypertens."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/hr.2009.175","article-title":"Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction","volume":"33","author":"Ito","year":"2010","journal-title":"Hypertens. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1185\/03007995.2010.528282","article-title":"Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension","volume":"26","author":"Chrysant","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/jhh.2009.38","article-title":"Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: Results of a randomized, double-blind study","volume":"24","author":"Palatini","year":"2010","journal-title":"J. Hum. Hypertens."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1055\/s-0030-1263123","article-title":"Different Effects of Aliskiren and Losartan on Fibrinolysis and Insulin Sensitivity in Hypertensive Patients with Metabolic Syndrome","volume":"42","author":"Fogari","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/1074248410377173","article-title":"Effects of High- and Low-Sodium Diets on Ambulatory Blood Pressure in Patients With Hypertension Receiving Aliskiren","volume":"15","author":"Weir","year":"2010","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jash.2011.01.006","article-title":"Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension","volume":"5","author":"Ferdinand","year":"2011","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/14656566.2011.580276","article-title":"Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: A three-way crossover study","volume":"12","author":"Fogari","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1751-7176.2010.00418.x","article-title":"Comparison of Aliskiren\/Hydrochlorothiazide Combination Therapy With Hydrochlorothiazide Monotherapy in Older Patients With Stage 2 Systolic Hypertension: Results of the ACTION Study","volume":"13","author":"Basile","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1751-7176.2011.00552.x","article-title":"Comparison of Aliskiren\/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus","volume":"13","author":"Townsend","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","article-title":"Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): A randomised, parallel-group trial","volume":"377","author":"Brown","year":"2011","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11590280-000000000-00000","article-title":"Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension","volume":"31","author":"Sica","year":"2011","journal-title":"Clin. Drug Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1751-7176.2010.00416.x","article-title":"Peripheral and Central Blood Pressure Responses of Combination Aliskiren\/Hydrochlorothiazide and Amlodipine Monotherapy in African American Patients With Stage 2 Hypertension: The ATLAAST Trial","volume":"13","author":"Ferdinand","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jash.2011.08.003","article-title":"Validation of a therapeutic scheme for the treatment of resistant hypertension","volume":"5","author":"Segura","year":"2011","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1751-7176.2011.00483.x","article-title":"Comparative Efficacy and Safety of Combination Aliskiren\/Amlodipine and Amlodipine Monotherapy in African Americans With Stage 2 Hypertension","volume":"13","author":"Black","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/jhh.2010.38","article-title":"Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome","volume":"25","author":"Krone","year":"2011","journal-title":"J. Hum. Hypertens."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11591970-000000000-00000","article-title":"Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan\/HCT Combination","volume":"11","author":"Drummond","year":"2011","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1185\/03007995.2010.537318","article-title":"Efficacy and tolerability of aliskiren 300 mg\/hydrochlorothiazide 25 mg (\u00b1amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg","volume":"27","author":"Schweizer","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/hr.2011.150","article-title":"Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension","volume":"35","author":"Zhu","year":"2012","journal-title":"Hypertens. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jash.2011.11.004","article-title":"Comparison of the effects of aliskiren\/valsartan in combination versus valsartan alone in patients with Stage 2 hypertension","volume":"6","author":"Flack","year":"2012","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/HJH.0b013e328351c263","article-title":"Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan","volume":"30","author":"Brunel","year":"2012","journal-title":"J. Hypertens."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1185\/03007995.2011.637914","article-title":"Efficacy and tolerability of the single-pill combination of aliskiren 300 mg\/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg\/amlodipine 10 mg","volume":"28","author":"Axthelm","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1463-1326.2011.01535.x","article-title":"Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus","volume":"14","author":"Fogari","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2174\/157016112803520945","article-title":"Efficacy and tolerability of aliskiren\/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy\u00a5","volume":"10","author":"Pfeiffer","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1177\/0091270011426432","article-title":"Efficacy, Safety, and Tolerability of Aliskiren Monotherapy Administered With a Light Meal in Elderly Hypertensive Patients: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Evaluation Study","volume":"52","author":"Villa","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/HJH.0b013e328356b8ea","article-title":"Clinic and ambulatory blood pressure lowering effect of aliskiren\/amlodipine\/hydrochlorothiazide combination in patients with moderate-to-severe hypertension","volume":"30","author":"Taddei","year":"2012","journal-title":"J. Hypertens."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1751-7176.2012.00706.x","article-title":"Safety and Efficacy of Aliskiren\/Amlodipine\/Hydrochlorothiazide Triple Combination in Patients With Moderate to Severe Hypertension: A 54-Week, Open-Label Study","volume":"14","author":"Murray","year":"2012","journal-title":"J. Clin. Hypertens."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2174\/157016112803520765","article-title":"Antihypertensive efficacy and tolerability of aliskiren\/amlodipine single-pill combinations in patients with an inadequate response to aliskiren monotherapy","volume":"10","author":"Glorioso","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1742-1241.2012.02967.x","article-title":"Treatment with aliskiren\/amlodipine combination in patients with moderate-to-severe hypertension: A randomised, double-blind, active comparator trial","volume":"66","author":"Shustov","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1751-7176.2012.00640.x","article-title":"Effects of Aliskiren-Based Therapy on Ambulatory Blood Pressure Profile, Central Hemodynamics, and Arterial Stiffness in Nondiabetic Mild to Moderate Hypertensive Patients","volume":"14","author":"Kanaoka","year":"2012","journal-title":"J. Clin. Hypertens."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/jhh.2012.42","article-title":"Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: A randomized, double-blind, multifactorial study","volume":"27","author":"Littlejohn","year":"2013","journal-title":"J. Hum. Hypertens."},{"key":"ref_75","first-page":"461","article-title":"Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects","volume":"61","author":"Mazza","year":"2013","journal-title":"Minerva Cardioangiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jch.12032","article-title":"Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren\/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus","volume":"15","author":"Bakris","year":"2013","journal-title":"J. Clin. Hypertens."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1536\/ihj.54.88","article-title":"Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension","volume":"54","author":"Yoshitomi","year":"2013","journal-title":"Int. Heart J."},{"key":"ref_78","first-page":"78","article-title":"The effect of aliskiren versus ramipril-based treatment on the Ambulatory Arterial Stiffness Index in hypertensive patients","volume":"33","author":"Andreadis","year":"2014","journal-title":"Int. Angiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/1470320314530018","article-title":"Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria","volume":"16","author":"Imbalzano","year":"2015","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jch.12618","article-title":"Differing Effects of Aliskiren\/Amlodipine Combination and High-Dose Amlodipine Monotherapy on Ambulatory Blood Pressure and Target Organ Protection","volume":"18","author":"Mizuno","year":"2016","journal-title":"J. Clin. Hypertens."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2169\/internalmedicine.55.5629","article-title":"Antihypertensive Efficacy of the Direct Renin Inhibitor Aliskiren as Add-on Therapy in Patients with Poorly Controlled Hypertension","volume":"55","author":"Tani","year":"2016","journal-title":"Intern. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/jhh.2008.162","article-title":"Blood pressure lowering efficacy of renin inhibitors for primary hypertension: A Cochrane systematic review","volume":"23","author":"Musini","year":"2009","journal-title":"J. Hum. Hypertens."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1753944710369682","article-title":"Aliskiren versus ramipril in hypertension","volume":"4","author":"Verdecchia","year":"2010","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ajh.2011.3","article-title":"Aliskiren vs. Angiotensin Receptor Blockers in Hypertension: Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"Gao","year":"2011","journal-title":"Am. J. Hypertens."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1470320310381912","article-title":"A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension","volume":"12","author":"Zheng","year":"2011","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/hr.2012.185","article-title":"Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: A meta-analysis","volume":"36","author":"Chen","year":"2013","journal-title":"Hypertens. Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Liu, Y., Chen, K., Kou, X., Han, Y., Zhou, L., and Zeng, C. (2013). Aliskiren and Amlodipine in the Management of Essential Hypertension: Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070111"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/ajh\/hpt210","article-title":"Aliskiren\/Amlodipine vs. Aliskiren\/Hydrochlorothiazide in Hypertension: Indirect Meta-Analysis of Trials Comparing the Two Combinations vs. Monotherapy","volume":"27","author":"Liu","year":"2014","journal-title":"Am. J. Hypertens."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.amjhyper.2004.05.017","article-title":"Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled","volume":"17","author":"Bramlage","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/HJH.0b013e32832be593","article-title":"Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: Sub-analysis of a 52-week, randomized, double-blind trial","volume":"27","author":"Schmieder","year":"2009","journal-title":"J. Hypertens."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1742-1241.2010.02562.x","article-title":"Antihypertensive effectiveness of aliskiren for the \u201creal-world\u201d management of hypertension: Multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study)","volume":"65","author":"Verpooten","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"ref_93","first-page":"1","article-title":"AIFA Drug Monitoring Program: Aliskiren Registry Use of aliskiren in a \u201creal-life\u201d model of hypertension management","volume":"30","author":"Volpe","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12325-013-0005-8","article-title":"Effectiveness and Safety of Aliskiren and Aliskiren Hydrochlorothiazide (HCT) in a Multiethnic, Real-World Setting","volume":"30","author":"Maddury","year":"2013","journal-title":"Adv. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijcard.2014.07.089","article-title":"3A Registry Investigators 1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: Prospective 3A registry","volume":"176","author":"Zeymer","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00508-015-0748-0","article-title":"Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren\/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study","volume":"127","author":"Rosenkranz","year":"2015","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"AVOID Study Investigators Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ. Hear. Fail."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/eurheartj\/ehq190","article-title":"Patients with acute coronary syndromes and elevated levels of natriuretic peptides: The results of the AVANT GARDE-TIMI 43 Trial","volume":"31","author":"Scirica","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/eurheartj\/ehq522","article-title":"Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction","volume":"32","author":"Solomon","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"ALTITUDE Investigators Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2013.277169","article-title":"Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension","volume":"310","author":"Nicholls","year":"2013","journal-title":"JAMA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/eurheartj\/ehu079","article-title":"Aliskiren Prevention of Later Life Outcomes trial Investigators Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: The APOLLO trial","volume":"35","author":"Teo","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"ASTRONAUT Investigators and Coordinators, for the Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"ATMOSPHERE Committees Investigators Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/eurjhf\/hfs033","article-title":"Aliskiren, ALTITUDE, and the implications for ATMOSPHERE","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ajh\/hpu119","article-title":"Effect of Aliskiren on Circulating Endothelial Progenitor Cells and Vascular Function in Patients With Type 2 Diabetes and Essential Hypertension","volume":"28","author":"Raptis","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/jch.12262","article-title":"Role of Aliskiren on Arterial Stiffness and Endothelial Function in Patients With Primary Hypertension","volume":"16","author":"Bonadei","year":"2014","journal-title":"J. Clin. Hypertens."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ajh\/hpt158","article-title":"Differential Effects of Aliskiren\/Amlodipine Combination and High-Dose Amlodipine Monotherapy on Endothelial Function in Elderly Hypertensive Patients","volume":"27","author":"Fukutomi","year":"2014","journal-title":"Am. J. Hypertens."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/6\/6\/61\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:38:31Z","timestamp":1760207911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/6\/6\/61"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":110,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["jcm6060061"],"URL":"https:\/\/doi.org\/10.3390\/jcm6060061","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]}}}